SCHEMBL5777751

SCHEMBL5777751

Cc1cc(C)c(S(=O)(=O)N[C@@H](C)C(=O)O)c(C)c1N

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.51
ADAMTS4 O75173 1/20 0.42
MMP1 P03956 2/20 0.40
MMP2 P08253 2/20 0.40
MMP3 P08254 2/20 0.40
MMP7 P09237 2/20 0.40
MMP9 P14780 2/20 0.40
MMP13 P45452 2/20 0.40
SLC1A3 P43003 2/20 0.38
SLC1A2 P43004 2/20 0.38
SLC1A1 P43005 2/20 0.38
ALDH1A1 P00352 1/20 0.36
CYP2C19 P33261 1/20 0.36
ALOX5AP P20292 1/20 0.36
FEN1 P39748 1/20 0.36
HTT P42858 1/20 0.35
PLAU P00749 2/20 0.35
PLG P00747 1/20 0.35
NR3C1 P04150 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5663653 0.80 MMP1 (0.55) KDM4EADAMTS4MMP1MMP2MMP3
SCHEMBL5664360 0.80 MMP1 (0.55) KDM4EADAMTS4MMP1MMP2MMP3
Valine SCHEMBL9352525 0.74 SLC1A3 (0.48) KDM4EADAMTS4MMP1MMP2MMP9
Valine SCHEMBL9348623 0.74 SLC1A3 (0.48) KDM4EADAMTS4MMP1MMP2MMP9
Trifluoroacetic Acid SCHEMBL7394766 0.72 NR3C1 (0.48) KDM4EADAMTS4MMP1MMP2MMP9
Trifluoroacetic Acid SCHEMBL5663234 0.72 NR3C1 (0.48) KDM4EADAMTS4MMP1MMP2MMP9
SCHEMBL15448833 0.71 ADAMTS4 (0.41) KDM4EADAMTS4ALDH1A1ALOX5APFEN1
SCHEMBL8627896 0.70 RAPGEF4 (0.38) KDM4EMMP1MMP2MMP9MMP13
SCHEMBL20335011 0.70 L3MBTL1 (0.58) ADAMTS4MMP1MMP2MMP3MMP7
SCHEMBL20335013 0.70 L3MBTL1 (0.58) ADAMTS4MMP1MMP2MMP3MMP7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0944619-B1 NOVEL INTEGRIN RECEPTOR ANTAGONISTS BRISTOL MYERS SQUIBB PHARMA CO (US) 2006-10-11 EP disclosed
US-6358976-B1 FOR THERAPY AND PROPHYLAXIS OF CANCER METASTASIS, DIABETIC RETINOPATHY, NEOVASCULAR GLAUCOMA, THROMBOSIS, RESTENOSIS, OSTEOPOROSIS, OR MACULAR DEGENERATION LANTHEUS MI REAL ESTATE, LLC 2002-03-19 US disclosed
US-6130231-A SUBSTITUTED 2,3-DIHYDROQUINOLIN-4-ONES DUPONT PHARMACEUTICALS (US) 2000-10-10 US disclosed